MOTS-c
A short peptide made by the body, with a sequence encoded in mitochondrial DNA. Research follows its role in muscle and cellular stress. Human observations do not yet establish what administering it would do for health.

Human findings, animal experiments, and the questions that remain.
Compare the researchMOTS-c and NAD+ both appear in research about how cells use energy. They belong to different chemical classes, and the studies behind them ask different questions. This guide keeps those distinctions visible, from the substance tested to the people or animals studied.
A short peptide made by the body, with a sequence encoded in mitochondrial DNA. Research follows its role in muscle and cellular stress. Human observations do not yet establish what administering it would do for health.
A coenzyme that helps enzymes carry out reactions, including those involved in energy metabolism. Human trials often test its building materials, NMN or NR. Their results need to keep the name of the substance actually studied.
See the chemistry, study designs, outcomes, and safety gaps together. The comparison makes room for the research without turning a shared interest in metabolism into evidence for using the two together.
An increase in a blood measurement can be real while its meaning for long-term health remains uncertain. A change in running capacity in mice can help researchers form a question for human studies. Neither result answers every question a reader may bring.
The 2025 review of human NAD+ precursor studies describes limited clinical efficacy and gaps in tissue measurements. The MOTS-c literature is largely preclinical: work in cells and animals. Evidence has a setting, and that setting matters.

Read findings with the population, preparation, and measured outcome beside them. These are useful checks whether a headline concerns cellular chemistry, exercise, or aging.
Was a substance given to people, and was there a comparison group? The NAD+ page separates oral precursor results from other routes.
A mechanism can be well described while human benefit remains untested. The MOTS-c page identifies where the experiments took place.
Short studies cannot settle every long-term risk. Missing human safety data deserve as much attention as a promising result.
The papers covered here do not establish a human regimen for NAD+ with MOTS-c. Shared pathways alone cannot supply one.
The FAQ addresses the words that often get blurred: peptide, precursor, biomarker, and clinical benefit.
The references describe the original studies and official safety material, with direct links for a closer read.